Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2019 | REACH safety data: avelumab plus RT-cetuximab in LA SCCHN

Jean Bourhis • 27 Sep 2019
ESMO 2019
Head and Neck Cancer Avelumab Cetuximab Checkpoint Inhibitors
REACH

Jean Bourhis, MD, PhD, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland, speaks at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain. Dr Bourhis discusses the safety and toxicity seen in the REACH study (NCT02999087) – a trial evaluating the use of avelumab when combined with cetuximab and radiation therapy in locally advanced squamous cell carcinoma of the head and neck (LA SCCHN).

More from Jean Bourhis

1:01
CRT and Debio1143 for treatment of LA SCCHN
Jean Bourhis • 27 Sep 2019

Related Videos

1:03
Challenges in implementing liquid biopsies for head and neck cancer
Mouadh Barbirou • 7 Apr 2024
2:43
Molecular profiling of tumor biomarkers in head and neck cancer
Mouadh Barbirou • 7 Apr 2024
1:40
The future of squamous cell carcinoma research at ESMO Asia 2023
Brian Henick • 6 Dec 2023
0:54
The role of immunotherapy in PD-L1 low advanced squamous cell carcinoma
Brian Henick • 6 Dec 2023
The content of VJOncology is intended for healthcare professionals